All News

Treatment for the polio virus may eventually move into the treatment realm for brain cancer, thanks to a breakthrough therapy designation by the FDA.

Despite educational and graphic antismoking ads and public service announcements, many young people still find the attraction outweighs the risks. How do we convince them otherwise?

A recent study where glioblastoma patients underwent laser surgery to kill tumors cells proved to have extra benefits, showing promise to treating the deadly disease.

The immunotherapy combination of Opdivo and Yervoy continues to show promise as it presented overall survival benefits for patients with advanced melanoma.

I had just moved to Minneapolis from Maui when I received my diagnosis of a glioblastoma multiforme.

I’ve found in myself, and many of the survivors I’ve met in counseling sessions, that of all the stages of grief, anger seems to have the greatest staying power.

After a phase 2 study, Lenvima and Afinitor gained FDA approval for the treatment of renal cell carcinoma.

The approval of atezolizumab will change the treatment paradigm of bladder cancer overnight, says Robert Dreicer.

Lung cancer is much more prevalent in men than women, yet is still not being looked at as a women's health issue, Andrea Wolf says.

There are as many ways to write a bucket list as there are personalities. Goals can be practical or dreamy, lists long or short. Some bucket lists are like drill sergeants, others a soft voice whispering in your ear. If “write a bucket list” is on your bucket list, here are a few tips.

The novel therapy explored in this study is designed to help individuals in four areas: education, self-awareness, stress management and cognitive compensatory strategies.

Charles M. Perou discusses how lobular breast cancer subtypes are used in clinical practice, what researchers have learned from sequencing the genome and how determining intrinsic subtypes can help guide breast cancer therapy.

Many advances have been made regarding immunotherapy to treat melanoma, and there is also more to come, says Antoni Ribas.

Hand massage was proven to not only reduce patient anxiety while undergoing chemotherapy, but also to strengthen nurse-patient relationships.

Algenpantucel-L failed to improve OS for patients with pancreatic cancer in a phase 3 trial.

While there have been many recent groundbreaking advances in treating myeloma, Kenneth C. Anderson is optimistic that the future holds even more promise.

Insomnia can be a problem for many patients with breast cancer.

I am typing this as I wait to be called back for scans. The miracle of imaging and the advances that have been made in the 17 years since my diagnosis do not escape me. I will soon receive the results that will determine my next steps. I will never meet or know all of the people that it takes to create these images, to read the results, or even to help make important choices in moving forward.

In an interview with Hyman B. Muss, CURE gained insight into the complications, misconceptions and likely outcomes of patients who are simultaneously pregnant and battling breast cancer.

The FDA expanded the label for Imbruvica for some patients with CLL, as the drug continues to show improved survival benefits.

A recent phase 3 trial is exploring the question of whether or not smoldering multiple myeloma needs treatment.

A new three-drug combination is proving successful for patients with relapsed/refractory multiple myeloma, according to a phase 3 study.

Even those without the diagnosis have a lot to learn from cancer.

My dog helped me get through cancer and now my heart is breaking.

Stivarga (regorafenib) proved to have better overall survival for patients with HCC in a recent phase 3 trial.

“This is a small-site, single-arm study, but these preliminary data are encouraging,” says lead study author Roberto Pili. “It suggests that this combination of an HDAC inhibitor can induce a greater benefit with an immunotherapy — in this case, IL-2.”

Although it is often a sensitive topic to discuss, being obese puts women at a higher risk for developing — and dying from— endometrial cancer.

Despite advances in treatment for bladder cancer and RCC, there is still an unmet need for navigating biomarkers that will offer insight as to which patients will respond best to treatment.